Should MRI be the primary endpoint of phase III trials in MS? No

被引：0

作者：

Weinshenker, B. G. ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

107

引用

页码：28 / 28

页数：1

共 50 条

[21] Outcomes of patients not achieving primary endpoint from an ibalizumab Phase III trial
DeJesus, E.
Emu, B.
Weinheimer, S.
Cohen, Z.
Cash, B.
Lewis, S.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[22] Phase III study of ETEC vaccine does not meet primary clinical endpoint
不详
DRUG NEWS & PERSPECTIVES, 2000, 13 (02) : 114 - 114
[23] Section III - Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? Presentation III
Sacks, FM
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (8A): : 90F - 92F
[24] Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Sarah A. Holstein
Vera J. Suman
Philip L. McCarthy
Current Hematologic Malignancy Reports, 2019, 14 : 31 - 38
[25] Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, Sarah A.
Suman, Vera J.
McCarthy, Philip L.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 31 - 38
[26] Primary endpoints of phase III trials for older patients with cancer
Mizutani, T.
ANNALS OF ONCOLOGY, 2021, 32 : S1187 - S1187
[27] Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials
Petrelli, Fausto
Barni, Sandro
TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (01) : 6 - 13
[28] Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
Cheema, P. K.
Burkes, R. L.
CURRENT ONCOLOGY, 2013, 20 (02) : E150 - E160
[29] THERAPEUTIC TRIALS IN CORONARY-THROMBOSIS SHOULD MEASURE LEFT-VENTRICULAR FUNCTION AS PRIMARY ENDPOINT OF TREATMENT
NORRIS, RM
WHITE, HD
LANCET, 1988, 1 (8577): : 104 - 106
[30] Quality of life should be the primary outcome for disease modifying therapy trials in MS-No
Strijbis, E. M. M.
Koch, M. W.
de Jong, B. A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (09) : 1066 - 1067

← 1 2 3 4 5 →